Home / News / India News / Article / Sputnik's single-dose vax gets DCGI nod for Phase-III trials in India

Sputnik's single-dose vax gets DCGI nod for Phase-III trials in India

The nod comes after a recent study published in the medical journal The Lancet said that Sputnik Light showed 78.6 to 83.7 per cent efficacy against Covid-19, significantly higher than most two-shot vaccines

Listen to this article :
Photo used for representational purpose

Photo used for representational purpose

The Drugs Controller General of India (DCGI) has granted permission for the conducting of the Phase III bridging trials of Sputnik Light on the Indian population. The Sputnik Light is a single-dose Covid-19 vaccine of the Russian vaccine Sputnik.

The nod comes after a recent study published in the medical journal The Lancet said that Sputnik Light showed 78.6 to 83.7 per cent efficacy against Covid-19, significantly higher than most two-shot vaccines.

Trending Stories

Latest Photoscta-pos

Latest VideosView All

Latest Web StoriesView All

Mid-Day FastView All

Advertisement